Indian Pharma Market’s Growth Moderates Further In February: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Indian Pharma Market growth moderated further to 1.1% YoY in February 2021 versus 4.5% YoY in January 2021 (12.1% in February 2020).
The gastro, derma, and vitamin-mineral-nutrient therapies exhibited growth of 9.9% YoY, 9.6% YoY, and 8.6% YoY, respectively.
The Anti-Infective therapy declined 11.3% YoY vis-a-vis decline of 2.7% YoY in January 2021.
Respiratory sales continued on the downtrend with 20.3% YoY decline in February 2021.
National List of Essential Medicines (~16% of IPM) declined 3% YoY, while non-NLEM (~84% of IPM) grew 2% YoY.
On a moving annual turnover basis, industry growth came in at 1.9% YoY.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.